Cancer drug developer obtains $32.5M in private placement

05/3/2013 | American City Business Journals

Celator Pharmaceuticals, a New Jersey-based firm specializing in cancer drugs, secured $32.5 million in a private placement led by Valence Life Sciences. Proceeds will go toward the late-stage trial of CPX-351 liposome injection, the company's lead drug candidate for secondary acute myeloid leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA